IMO, I like the story but it’s not the story that's executing the [plan. That's the job of the storyteller - the CEO.
I can't express how bad of a decision it's been to leave the IPF and Chronic Cough clinical trial dragging out in Australia and New Zealand.
That is the biggest mistake yet on the CEO's watch.
It eclipses the fire in Romania where we could have lost 75% of our COVID-19 data but the results got pushed back by months right up to the last day of Q1 2021.
The IPF and Chronic Cough clinical trial continues to get pushed further and further back.
It started out with getting preliminary data for Chronic Cough in Q3 2020.
Then it became Q4 2020.
Then it became Q1 and Q2 2021.
Now it's Q something 2021.
But rest assured the company doesn't know and apparently has zero control over recruiting in Australia and New Zealand.
Going there was a decision made by management and they had to know it was a challenging market in the first place with having only 3 or 4 recruitment sites to start with.
it's become the biggest blunder to date because we don't have the data needed to push the needle forward.
Where would the stock price possibly be now had we gotten IPF and Chronic Cough data last year?
How about this past Q1 or now in Q2?
The IPF and Chronic Cough clinical trial is the 1st clinical trial out the gate for Algernon not COVID-19.
We are failing miserably at doing the Top Priority thing for a clinical trial Biotech which is getting to data readouts.
Nobody here would have predicted how we have lost all traction and momentum as a company if we rewind all the stories we've heard thus far about Ifenprodil.
We can/will never make it as a company with the type of execution of the repurposed drugs strategy thus far playing out.
We have only been good at diluting the company with Private Placements.
No talk of partnerships other than the CEO having stated other companies have called but what does that even mean for us shareholders?
I don't see how the company gets itself out of the latest ditch it's in without more than just positive news about moving to a phase 3 clinical trial for COVID-19.
We need a partnership deal to bring more legitimacy to the company and the market.
That's my two cents and if that's all I had invested here I'd just sit on my hands and say nothing.
Good luck to you in all your future endeavors talisman47.
BB